We describe a method for the determination of the two major urinary metabolites of vitamin K as the methyl esters of their agyclone structures, 2-methyl-3-(3΄-3΄-carboxymethylpropyl)-1,4-naphthoquinone (5C-side-chain metabolite) and 2-methyl-3-(5΄-carboxy-3΄-methyl-2΄-pentenyl)-1,4-naphthoquinone (7C-side-chain metabolite), by HPLC with electrochemical detection (ECD) in the redox mode.
INTRODUCTION
Compounds with vitamin K activity have a common 2-methyl-1, 4-naphthoquinone nucleus and a variable alkyl substituent at the 3 position. The major naturally occurring K vitamins are the plant form phylloquinone (vitamin K 1 ) and multiple forms of menaquinones (vitamins K 2 ), predominately of bacterial origin.
Phylloquinone (abbreviated K 1 ) has a 20-carbon, phytyl side chain whereas menaquinones have multi-prenyl side chains, their number being indicated by a suffix (i.e. menaquinone-n, abbreviated MK-n). In a typical Western diet, K 1 and MK-n account for about 90% and 10% of vitamin K intakes respectively (1) . Dietary MK-n mainly comprise MK-4, MK-7, MK-8, and MK-9 (2), although MKs with longer side chains up to MK-13 are present in human liver (3, 4) . Menadione (abbreviated K 3 ) is a synthetic vitamin K homologue that lacks the side chain at the 3-position and which, despite toxicity issues and restricted biological activity, is still available in some countries as a pharmaceutical vitamin K preparation in the form of menadiol sodium phosphate (5) or similar water-soluble salt. The biological activity of K 3 in vivo depends entirely on its prenylation to MK-4 (6,7).
At the cellular level the cofactor role of vitamin K for the post-translational conversion of specific peptide-bound glutamate (Glu) to g-carboxyglutamate (Gla) is well established as is the intimately associated metabolic cycle whereby the vitamin K 2,3 epoxide metabolite generated during g-glutamyl carboxylation is salvaged (8) (9) .
Other aspects of the intermediary metabolism of vitamin K, including the processes leading to vitamin K catabolism and excretion, are much less understood.
During the 1970's human studies employing radio-labelled-tracer and unlabelled pharmacological doses showed that K 1 was rapidly and extensively catabolised via the urine and bile (10) (11) (12) . These studies established that the major aglycone metabolites of K 1 were two side-chain shortened carboxylic acids with the structures 2-methyl-3-(3¢-3¢-carboxymethylpropyl)-1,4-naphthoquinone (side chain length 5 carbon atoms, structure IV in Fig. 1 ) and 2-methyl-3-(5¢-carboxy-3¢-methyl-2¢-pentenyl)-1,4-naphthoquinone (side chain length 7 carbon atoms, structure III in Fig.   1 ) respectively. (10) (11) (12) . Both 5C-and 7C-aglycones were excreted as watersoluble conjugates, mainly with glucuronic acid.
At the time of isolation and characterization of these two metabolites (henceforward abbreviated to 5C-and 7C-aglycones respectively), the role of vitamin K was thought to be limited to its classical coagulation function, and human deficiency at the population level was only considered a problem during the first 6-months of life (13) . However the subsequent discovery of many more vitamin Kdependent proteins (also called Gla proteins), with a widespread tissue distribution, has lead to a re-evaluation of the general physiological function and health roles of vitamin K. Putative roles of Gla proteins now extend to a diversity of functions such as the regulation of bone turnover and calcification (14) (15), inhibition of vascular calcification (16) , and roles in vascular repair processes (17) , cell cycle regulation, cell-cell adhesion, and signal transduction (18) . Of particular note is the accumulating body of evidence that has linked a suboptimal vitamin K reserves in bone to an increased risk of osteoporotic fracture (19) (20) or to reduced bone mineral density (21) . To address this issue, and other questions, there has been a need to develop new biochemical measures to monitor vitamin K status in human populations (22) .
Current measures include the direct measurement of circulating vitamin K (as an indicator of tissue stores) and functional assessments of the g-carboxylation status of specific Gla proteins such as prothrombin and osteocalcin representing hepatic and bone g-carboxylation capacity respectively. In addition, measurements of urinary free Gla offer an overall assessment of the g-carboxylation status of Gla proteins. Each of these status assessments has a number of methodological and interpretational drawbacks (23) (24) (25). Although useful in many situations, the measurement of circulating vitamin K to assess tissue stores has the major disadvantage that only K 1 is commonly measured to the detriment of MKs. MKs from the diet (1) (2) and possibly from intestinal synthesis (3) (4) may make a significant contribution to total daily vitamin K intake (1) , and the liver stores of vitamin K are predominately long chain MKs (3) (4).
Here we describe the development of chromatographic techniques to quantify the two major urinary aglycones of vitamin K with high sensitivity, enabling their measurement at low physiological concentrations. We chose ECD in the redox mode for the final analytical HPLC stage as this method is especially suitable for quinone compounds and has been successfully used for the determination of vitamin K in serum (26) (27). To find out whether the 5C-and 7C-aglycones are common to all K vitamins, we obtained urine samples from adults before and after supplementation with different doses of K 1 , MK-4, MK-7 and K 3 . We also analysed urine samples from newborn infants who, as a group, are known to have precariously low vitamin K stores, and are routinely given vitamin K prophylaxis at birth. The  5C-aglycone  (2-methyl-3-(3΄-3΄-carboxymethylpropyl) 
MATERIALS AND METHODS

Reagents
Urine collection and human subject protocols
Twenty four-hour and spot urine collections were made into plastic containers.
Owing to the photosensitive nature of the metabolites, the urine containers were protected from sources of strong light. Urine collections were stored at room temperature for the duration of the collection period and aliquots frozen at -70°C until analysis. No significant metabolite loss occurred under these conditions.
We investigated urinary 5C-and 7C-aglycone excretion in healthy adult A number of spot urines were also collected from newborn infants (2 males, 1 female) before and after intramuscular K 1 prophylaxis with 1 mg Konakion Neonatal (Roche, Basel, Switzerland).
All adult volunteers and guardians of newborns gave full written informed consent prior to participation in these investigations.
Assay Procedure
A flowchart showing the extraction and analytical procedures is shown in Fig. 2 .
Extraction and hydrolysis of metabolites
A C 18 SPE cartridge was pre-washed with 1ml of methanol followed by 1 ml of deionised water. Aliquots of 0.5 ml (unsupplemented subjects) or 0.05 ml (after vitamin K supplementation) of urine were loaded onto the SPE cartridge and allowed to elute to waste under gravity. To remove urinary salts, the SPE cartridge was washed with 1 ml of deionised water at a flow rate of ~0.5 ml/min and the eluent discarded (32) . The conjugated vitamin K metabolites were then eluted into a clean tapered polypropylene test tube (12 ml capacity) with 2 ml of a methanolic stock solution containing 0.15 mg of the IS and the eluent evaporated to dryness under a stream of N 2 at 50°C.
Conjugated urinary vitamin K metabolites were hydrolysed overnight at room temperature (in the dark) with 1.1 ml of methanolic HCl (prepared by combining one volume of concentrated (35%) HCl with 4 volumes of methanol) (33) . The metabolites, now as their aglycones, were extracted into chloroform by the addition of 1.1 ml chloroform and 1.0 ml water to the sample tube (34) . The upper methanolicaqueous layer was removed, and discarded. To prevent acid-catalysed lactonisation of the 7C-aglycone during subsequent drying procedures, the lower chloroform layer was washed with 10 ml of deionised water to remove any residual mineral acid. After brief shaking, and allowing the two phases to separate, the upper aqueous layer was discarded and the lower chloroform layer evaporated to dryness under a stream of N 2 at 50˚C.
Methylation of aglycones
The carboxylic acid forms of the vitamin K aglycones were converted to their methyl ester derivatives by reaction with freshly prepared ethereal diazomethane generated on a small scale by a modification of a method described elsewhere (35) . In brief, a mixture of 5M KOH (~20 ml) and diethyl ether (~15 ml) are placed into a small, screw capped bottle (100 ml-capacity Duran) and solid MNNG gradually added until sufficient diazomethane has been generated to turn the upper ether layer yellow (Caution: only perform in well-ventilated fume hood). A volume of 0.5 ml of this ethereal diazomethane was then added to each urine extract. Complete methylation of the carboxylic acid group of the aglycone-metabolites was achieved at room temperature within 5 minutes after which the diethyl ether was removed under a stream of N 2 at 50°C.
Normal-phase SPE of methylated aglycones
Further fractionation of the urine extract was achieved by normal phase-SPE using Sep-Pak™ cartridges. Each cartridge was attached to a 10-ml glass syringe with a Luer end fitting and activated by drawing through 2 ml of n-hexane. Each extract, was dissolved in 2 ml of n-hexane, and then pipetted into the glass syringe attached to the activated cartridge. The n-hexane was drawn through the cartridge and the eluent discarded. A further volume of 8 mL of n-hexane was added to the sample tube, the washings drawn through the cartridge, and discarded as before. The vitamin K metabolites and IS were then eluted from the cartridge with 10 ml of nhexane-diethyl ether (85:15, v/v), and collected into a fresh polypropylene, stoppered, tapered test tube. The solvent was removed under a stream of nitrogen at 50° C.
Reversed-phase HPLC-ECD
The final separation of the methylated aglycones was achieved by reversedphase HPLC using a Thermo Hypersil-Keystone HyPURITY C 18 column (3mm Chromatograms were generated by monitoring the current (nA) at the wall jet electrode.
Quantification of 5C-and 7C-aglycone metabolites
From methanolic stock solutions of the 5C-and 7C-aglycones and the IS (methyl ester forms) we prepared a series of standards containing all 3 analytes with spectrophotometrically determined (E mM = 18.9 at 248 nm) weight ratios of 5C-aglycone/IS and 7C-aglycone/IS ranging from 0.003 to 0.121. Each chromatographic run included the direct injection of 10 ml of each calibration standard. For routine analyses (i.e. for physiological urinary concentrations of metabolites) the SPEfractionated extracts were reconstituted in 40 ml of methanol and a volume of 10 ml injected onto the RP-HPLC system. For the determination of the much higher levels after vitamin K supplementation, the extract was reconstituted in 100 ml of methanol and 10 ml injected. Metabolite concentrations were quantified by the method of peakheight ratios. For each chromatogram generated, the peak heights of 5C-and 7C-aglycones were expressed as a ratio to the IS peak. A calibration plot of peak height ratios of the standards versus their weight ratios gave excellent linearity (r 2 typically ≥ 0.999) and was used to calculate the equivalent weight ratios of aglycone/IS for each unknown. Multiplication of this weight ratio by the amount of IS originally added gave the amounts of aglycones in the volume of urine processed.
RESULTS
Optimisation of extraction and conjugate-hydrolysis procedures
The initial SPE procedure using C 18 
Methyl ester derivatisation of carboxylic acid aglycones
There were two main reasons for adopting a pre-HPLC methylation procedure to quantitatively convert the aglycone carboxylic acids to their respective methyl esters. Firstly, exposure to methanol during the chromatographic procedures resulted in some inadvertent methylation, which was enhanced by use of methanolic HCl to deconjugate the aglycones. Secondly, the reduced polarity of these methylated derivatives improved their retention in our RP-HPLC separation system.
SPE purification of methylated aglycones
An additional SPE purification stage using silica cartridges was introduced to remove interfering compounds, which prevented baseline resolution of the 5C-and 
Optimisation of HPLC-ECD Conditions
The hydrodynamic voltammograms of the 5C-and 7C-aglycone methyl esters together with the IS are shown in Fig. 3 . A voltage of -1.2 V was selected as the applied potential in the upstream flow-through coulometric twin electrodes for quantitative reduction of the quinone forms of metabolites and IS to their corresponding quinols (this was the maximum possible voltage to the electrodes of the ESA coulometric cell when controlled by the DECADE instrument). In selecting +0.3 V as the applied potential for the down stream amperometric electrode (for the re-oxidation of the respective quinols), a minimal degree of assay sensitivity was sacrificed. However this reduced interferences from co-extracted and cochromatographed substances and resulted in a reduced background current.
The EC reduction of the quinone to the quinol moiety was temperaturedependent. Increasing the temperature in which the reductive EC cell was housed improved overall sensitivity of the assay and we routinely operated the EC cells in the temperature range of 37-42°C. The methanol component of the mobile phase and system temperature were adjusted until the retention times of the 5C-aglycone, 7C-aglycone and IS at a flow rate of 1 ml/min were ca. 8, 12 and 32 minutes respectively.
Both reductive and oxidative EC cells were found to be robust and foul free after prolonged use.
Calibration, Sensitivity, and Precision of the HPLC -EC assay
The injection of varying amounts of the 5C-and 7C-aglycones and the IS gave good peak shapes and a linear detector response within and beyond the mass range used for quantification of the aglycones. Typical chromatograms of a calibration standard solution and urinary extracts from both unsupplemented and vitamin Ksupplemented subjects are shown in Fig. 4 . The 'on column' lower limit of detection of 5C-and 7C-aglycones (defined as 5 x baseline noise) was <3.5 fmol (<1 pg). The intra-and inter-assay co-efficients of variation (CV) for 5C-and 7C-aglycone determination in urine from a healthy, non-supplemented volunteer is shown in Table   1 .
Mineral acid catalysed lactonization of 7C-aglycone side chain
The 7C-aglycone in its acid form differs from the 5C-aglycone in having a double bond at the g-d position relative to the carboxyl group of the side chain.
Organic acids with this g,d-unsaturated structure are unstable to mineral acids and undergo cyclization to a 5-membered g-lactone ring structure. As has been previously demonstrated in radioisotopic studies, the 7C-aglycone in its carboxylic acid form is readily converted to 2-methyl-3-(5¢-carboxy-3¢-hydroxy-3¢-methylpentyl)-1,4-naphthoquinone lactone (vitamin K g-lactone, structure V in Fig. 1 ) under aqueous acidic conditions such as when mineral acid is used to release the aglycones from their conjugated forms in urine (10) (11) (12) . To find out whether we could demonstrate g-lactonization by HPLC, we subjected 0.5 ml aliquots of urine (urine collected from a volunteer who had ingested 50 mg of K 1 ) to hydrolysis with 1ml of aqueous 3M HCl at 70°C for 60 minutes. After aqueous HCl hydrolysis the aglycones were extracted with chloroform and subjected to the usual assay procedure.
Treatment with mineral acid completely abolished the peak that co-chromatographed with the 7C-aglycone standard and resulted instead in an extra peak that cochromatographed with authentic vitamin K g-lactone (data not shown). A peak of vitamin K g-lactone was not found in urine samples after hydrolysis of the metabolite conjugates with methanolic HCl hydrolysis or enzyme preparations of bglucuronidase (also containing sulfatase).
Confirmation of chromatographic peak identification
Identification of the 5C-and 7C-methyl ester aglycone chromatographic peaks isolated from urine was initially achieved by confirming that they had identical chromatographic and chemical properties to the authentic synthetic standards. The chemical similarities between analytes and standards included their hydrodynamic voltammograms, their sensitivity to light and, for the 7C-aglycone, the lability towards mineral acid and conversion to a compound chromatographically indistinguishable from vitamin K g-lactone. Definitive confirmation of correct peak assignment was provided by in vivo studies that confirmed that the chromatographic measurements responded to supplementation with different forms of vitamin K.
Typical concentrations (corrected for creatinine) of 5C-and 7C-aglycones in urine samples collected on two consecutive days from 5 healthy, fasting adults (subjects A-E) are shown in Table 2 . Table 2 also shows the increase in urinary concentrations of both aglycones in response to supplementation with K 1 , MK-4, MK-7 and K 3 in a dose-dependent manner. These studies provided confirmation of the chromatographic peak identity for the respective aglycones.
DISCUSSION
As far as we are aware this is the first method to have been developed for the routine measurement of the two major urinary aglycones of vitamin K. The method is sensitive requiring small sample volumes and the inter-assay precision was about 10%
for both 5C-and 7C-aglycones. Although we used the same principle of redox mode electrochemical detection as for a previous assay of the parent K vitamins (27) (36) the metabolite assay has proved to be much less susceptible to periodic loss of sensitivity. In the serum vitamin K assay, this often-rapid loss of sensitivity is thought to be due to passivation of the electrodes by adsorbed species of vitamin K and co-extracted non-polar lipids (27) (36) . The lack of significant electrode passivation in the present assay may be related to the greater polarity of the metabolites and co-extracted urinary components, which makes them less likely to adsorb to the carbon electrodes than the highly lipophilic vitamin K and other lipids present in serum extracts.
The 5C-and 7C-aglycones measured in this assay were derived by the chemical hydrolysis of conjugates by methanolic HCl. This method of hydrolysis was previously employed for the isolation of the urinary aglycones of ubiquinone-7 (33) and phylloquinone (37) from rabbit urine. Previous work from our laboratory has suggested that the majority of the 5C-and 7C-metabolites in human urine are excreted as glucuronides (10) (11). We also confirmed in this study (data not shown) that incubation of urine with b-glucuronidase released the same two 5C-and 7C-aglycones and gave identical chromatograms to those after methanolic HCl hydrolysis. This does not exclude the possibility of other conjugates being present since 2-methyl-1, 4-naphthoquinone (menadione, vitamin K 3 ), which lacks the side chain, has been shown to be excreted as both glucuronide and the sulfate conjugates of the quinol form in rats (38) (39) and rabbits (40) . For routine quantitative analyses we chose methanolic HCl over enzymic hydrolysis for reasons of its greater convenience and efficiency, and to ensure complete hydrolysis of all conjugates present.
The results in Table 2 show that in both unsupplemented and supplemented adults, the excretion of the 5C-aglycone is greater than the excretion of the 7C-aglycone. This is in agreement with early radioisotopic measurements of these two aglycones after the administration of tritium-labelled phylloquinone to adults (10) (11). In the latter studies, the intravenous administration of single doses of 45-1000 mg of labelled phylloquinone resulted in a gradually increasing proportion of the 7C-aglycone (assayed as vitamin K g-lactone after acid hydrolysis) from an initial 13% to some 30-40% in successive urine collections made over the first 24 hours (10). In rabbits, the administration of a huge (91 mg) intravenous dose of phylloquinone changed the percentage proportion of 7C-aglycone (in 24-hour urine collections) from 13% in control animals to 57% post-supplementation (37) . This data suggests that whereas physiological amounts of phylloquinone are largely metabolised to the terminal 5C-aglycone, vitamin K supplementation may lead to a greater urinary excretion of the less extensively metabolised 7C-aglycone. Interestingly, one of the infants studied here (Infant A, Table 2 ) excreted predominately the 7C-aglycone after supplementation with 1 mg K 1 . Further support that large doses may overload the pathway comes from the previous isolation and definitive identification of a 10C-side chain length aglycone after a very large phylloquinone dose (12) . No evidence for this 10C-aglycone was seen on our chromatograms. Although the preliminary supplementation studies shown in Table 2 using the present assay showed doserelated increases in the urinary concentrations of both 5C-and 7C-aglycones, there was no consistent pattern in their relative concentrations. The supplementation studies with K 1 and members of the menaquinone series (MK-4 and MK-7) clearly indicate that the 5C-and 7C-aglycones are common to the major naturally occurring forms of vitamin K (Table 2 ). Although the excretion of different forms of vitamin K as these two common catabolites has not been formally demonstrated before, it was to be expected in view of previous work that has shown that the isoprenoid side chains of ubiquinone-7 (33), K 1 (11, 37) , a-tocopherol (37) (41) and d-tocopherol (42) are all shortened in the same way and excreted as equivalent metabolites.
The proposed degradation pathway (Fig. 1) of vitamin K by successive w-and b-oxidation is supported by the previous unambiguous identification of 5C-and 7C-aglycones (11), the finding of the expected 10C-side chain intermediate (12) and by analogy to the findings of others that the same degradation pathway operates for similar isoprenoid compounds (33) (42) (41).
The increase in 5C-and 7C-aglycone excretion in response to supplementation with K 3 is noteworthy. The generation of MK-4 from K 3 through the addition of a geranyl-geranyl side chain is well described (6) (7), and is the probable source of the increased excretion of the 5C-and 7C-aglycones following K 3 supplementation. It may be possible to use this metabolite assay as an index of the tissue conversion of K 3
to MK-4.
Our ongoing work is directed at evaluating the present assay as a new marker of vitamin K status. An obvious advantage over current serum measurements of vitamin K is that the urinary excretion reflects degradation of all K vitamins whereas most serum assays are only directed at the assay of a single vitamer, K 1 . Thus the measurement of urinary excretion might be suitable as a measure of overall vitamin K status. The relative contribution to total urinary excretion from K 1 and MKs remains to be determined. It seems likely that the majority of daily variability stems from excretion of K 1 since this is by far the major dietary form, and long-chain MKs are thought to have a slower turnover (43) . In addition to the prerequisite for normal renal function, a possible disadvantage of urinary measurements as a marker of vitamin K stores is that metabolites of vitamin K are also excreted via the bile so that urinary excretion will not reflect the total elimination of vitamin K from the body. Two separate urine collections from healthy subjects were analysed for the 5C-and 7C-aglycone metabolites of vitamin K to assess inter-assay (A) and intra-assay reproducibility (B) respectively. *Inter-assay reproducibility was assessed over a period of 5 months. * Unsupplemented healthy adult subjects A-E collected spot urines at 0900 on consecutive days after a 14 hr fast. **Supplemented healthy adult subjects F-N took the indicated vitamin K supplement orally and collected urine pre-and post-supplementation. The pre-supplementation urines for subjects F-L were 24-hour collections and for subjects M-N were spot urines (early AM) immediately prior to taking the vitamin K supplement. The post-supplementation urines were either spot urines collected at the time indicated (subjects F, and K-N) or entire 24-hour collections (subjects G-J).
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